FDA Approves Drug for PET Imaging of Prostate Cancer
Approval of Gallium 68 PSMA-11 provides new imaging approach to detect prostate cancer metastasis or recurrence.
Approval of Gallium 68 PSMA-11 provides new imaging approach to detect prostate cancer metastasis or recurrence.
Black, Hispanic patients less likely to receive recommended imaging at time of diagnosis of NSCLC.
Similar survival seen for PET-CT-guided surveillance and planned neck dissection, but fewer operations.
Positron emission tomography (PET) imaging may offer a superior method of imaging for metastatic prostate cancer.
PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.
From 1998 to 2007, more PET scans for married, non-black, <80-year-old patients with lung cancer were performed.
Advances in imaging for breast cancer screening, diagnosis, and response assessment are more promising now than ever before.
F-18-FDG PET more sensitive, equally specific to CT for assessing regional lymph node involvement.
Doctors may be able to use pretreatment PET imaging to better fight aggressive cancers, according to a study presented at the 2010 Multidisciplinary Head and Neck Cancer Symposium in Chandler, Arizona.